Anna Rostedt Punga
Professor at Institutionen för medicinska vetenskaper; Klinisk neurofysiologi
- Telephone:
- +46 18 471 49 41
- E-mail:
- anna.rostedt.punga@neuro.uu.se
- Visiting address:
- Rudbecklaboratoriet C11, Dag Hammarsköldsv 20
75237 UPPSALA - Postal address:
- Rudbecklaboratoriet C11, Dag Hammarsköldsv 20
75237 UPPSALA
- Academic merits:
- MD PhD, Associate Professor, Consultant
- CV:
- Download CV
More information is available to staff who log in.
Short presentation
This text is not available in English, therefore the Swedish version is shown.
Den röda tråden i min forskning är neurofysiologi och framförallt störd signalering mellan nerver och muskler och sjukdomen Myasthenia Gravis (MG), som leder till ökad muskeltrötthet.Vi arbetar med att hitta pålitliga biomarkörer för MG, bland annat så kallade mikroRNA. Genom en ny unik modell där nerv-och muskelceller odlas på ett elektroniskt chip kan vi spåra detaljerade processer i nerv-muskelsignaleringen och hoppas på sikt kunna få bättre sjukdomsförståelse och utveckla nya läkemedel.
Keywords
- myasthenia gravis
- neurofysiologi
- neuromuskulär
Biography
Anna Rostedt Punga studied medicine with emphasis on research at the faculty of Medicine, Uppsala University, and already then, she started conducting clinical research on myasthenia gravis (MG) in 1999. She spent 3 months at the Duke MG Clinic with Dr Donald Sanders at a scholarship from the Myasthenia Gravis Foundation of America. She later qualified as an MD in 2005 and subsequently defended her PhD thesis with focus on different antibody subtypes MG in the department of Neuroscience, Uppsala University, in 2007. Her postdoctoral studies, that focused on preclinical research on the neuromuscular junction in Basel, rendered an international award from the German Myasthenia Gravis Foundation (Eberhardt Pfleiderer Prize). In 2014 she was granted a highly competitive clinical research grant from the Swedish Research Council (success rate 8%) and then built her own research group/lab on MG and the neuromuscular junction at BMC, Uppsala University.
The research focuses on improving diagnostic and monitoring tools in MG, including biomarkers and neurophysiology, both in-vivo and in-vitro, as well as novel treatment options. At the moment, she holds multiple highly competitive national research grants from the Swedish Research Council and was recently awarded Göran Gustafssons large prize in medicine for my studies in MG. Her team has pioneered the field of microRNA biomarker discovery in MG and has several publications on this topic.
Anna Rostedt Punga combines the role of professor of clinical neurophysiology with a clinical position as consultant clinical neurophysiologist at the Department of Clinical Neurophysiology, Uppsala University Hospital. She also sees MG patients from all over Sweden in the Neurology outpatient unit at Uppsala University hospital. Further, she is the responsible physician for ongoing communication of research to the Swedish NEURO association of MG patients, connecting research with the stakeholder´s community.
She has published more than 50 peer-reviewed original articles as well as 8 review articles and 2 book chapters.
Publications
Recent publications
- Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome (2023)
- Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis (2023)
- Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis (2023)
- Keeping up appearances (2023)
- Implementation of tailored exercise programs for MG patients in a gym setting (2023)
All publications
Articles
- Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome (2023)
- Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis (2023)
- Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis (2023)
- Keeping up appearances (2023)
- Implementation of tailored exercise programs for MG patients in a gym setting (2023)
- Towards Personalized Medicine in Myasthenia Gravis (2022)
- Novel pathogenic ALG2 mutation causing congenital myasthenic syndrome (2022)
- Ultrathin Gold Microelectrode Array using Polyelectrolyte Multilayers for Flexible and Transparent Electro-Optical Neural Interfaces (2022)
- Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis The RINOMAX Randomized Clinical Trial (2022)
- Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders (2022)
- Enrichment of serum IgG4 in MuSK myasthenia gravis patients (2022)
- Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients (2021)
- Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies (2021)
- miR-1933-3p is upregulated in skeletal muscles of MuSK+ EAMG mice and affects Impa1 and Mrpl27 (2020)
- Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs (2020)
- Myasthenia gravis patient and physician opinions about immunosuppressant reduction (2020)
- Myasthenia Gravis and Physical Exercise (2020)
- Editorial (2020)
- Botulinum toxin injections associated with suspected myasthenia gravis (2020)
- Flodvåg av långtidssjuka covid-19-patienter väntar (2020)
- Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis (2020)
- Mortality rates and causes of death in Swedish Myasthenia Gravis patients (2020)
- Epidemiology of Myasthenia Gravis in Sweden 2006-2016 (2020)
- Inflammatory and anti-inflammatory markers in plasma (2019)
- Pattern of Habitual Physical Exercise in Myasthenia Gravis Patients (2019)
- Study protocol for a randomised controlled trial with clinical, neurophysiological, laboratory and radiological outcome for surgical versus non-surgical treatment for lumbar spinal stenosis (2019)
- Facing the challenges of electrodiagnostic studies in the very elderly (>80 years) population (2019)
- Cognitive dysfunction in mice with passively induced MuSK antibody seropositive myasthenia gravis (2019)
- miR-30e-5p as predictor of generalization in ocular myasthenia gravis (2019)
- Long-Term High-Density Extracellular Recordings Enable Studies of Muscle Cell Physiology (2018)
- Thymectomy lowers the myasthenia gravis biomarker miR-150-5p (2018)
- Reply to "high abnormal rate in the repetitive nerve stimulation test in acute onset myasthenia gravis" (2018)
- Circulating microRNAs as potential biomarkers in myasthenia gravis patients. (2018)
- Circulating microRNA plasma profile in MuSK plus myasthenia gravis (2018)
- Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis (2018)
- Advances in autoimmune myasthenia gravis management (2018)
- Lifestyle factors and disease-specific differences in subgroups of Swedish Myasthenia Gravis (2018)
- The impact of physical exercise on neuromuscular function in Myasthenia gravis patients (2018)
- Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles (2017)
- Diagnostic Utility of Repetitive Nerve Stimulation in a Large Cohort of Patients With Myasthenia Gravis (2017)
- Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. (2017)
- High-resistance strength training does not affect nerve cross sectional area – An ultrasound study (2017)
- Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries (2017)
- Physical exercise in Myasthenia Gravis is safe and improves neuromuscular parameters and physical performance-based measures (2017)
- Low vitamin D levels in healthy controls and patients with autoimmune neuromuscular disorders in Greece (2016)
- Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized Myasthenia Gravis (2016)
- Compound Motor Action Potential (2016)
- A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines (2016)
- Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. (2016)
- Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis (2015)
- Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients (2015)
- Regional Diffusion of Botulinum Toxin in Facial Muscles (2015)
- How clinical trials of myasthenia gravis can inform pre-clinical drug development (2015)
- Correlation of Botulinum Toxin Dose with Neurophysiological Parameters of Efficacy and Safety in the Glabellar Muscles (2014)
- Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies (2014)
- Circulating miRNAs in myasthenia gravis (2014)
- Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK plus ) experimental autoimmune Myasthenia gravis (EAMG) (2013)
- beta-glucans reduce LDL cholesterol in patients with myasthenia gravis (2013)
- Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3 (2012)
- Neurophysiological characteristics of MuSK antibody positive Myasthenia Gravis mice (2012)
- Usefulness of assessing repeater F-waves in routine studies (2012)
- Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS (2012)
- Signaling and aging at the neuromuscular synapse (2012)
- MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity (2011)
- Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice (2011)
- Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate (2009)
- Acetylcholinesterase inhibitors in myasthenia gravis (2009)
- Indication of peripheral nerve hyperexcitability in adult-onset subacute sclerosing panencephalitis (SSPE) (2008)
- Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis (2007)
- Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire (2006)
- Correlation between regional myasthenic weakness and mental aspects of quality of life (2006)
- Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes (2006)
- Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody (2006)
- Validation of the Swedish version of the disease- specific myasthenia gravis questionnaire. (2006)
- Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in myasthenia gravis patients (2005)
- Evaluation of motor unit potential parameters in relation to morphology of skeletal muscles culture on MEA chips
- Evaluation of muscle action potential parameters in relation to morphology of skeletal muscle cell culture on high-density microelectrode array chips
- Clinical and Neurophysiological Outcome of a Randomized Controlled Trial for the Treatment of Lumbal Spinal Stenosis
- Lifestyle factors and gender-related differences in clinical subgroups of Myasthenia Gravis in southern Sweden